| 02.05 13:31 | dpa-AFX: Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates |
| 02.05 12:44 | dpa-AFX: *REGENERON Q1 GAAP NET INCOME $722 MLN; NON-GAAP NET INCOME $1.12 BLN |
| 02.05 12:44 | dpa-AFX: *REGENERON Q1 REVENUES DOWN 1% TO $3.15 BLN |
| 02.05 12:37 | dpa-AFX: *REGENERON PHARMA Q1 GAAP EPS $6.27 AND NON-GAAP EPS $9.55 |
| 25.03 12:46 | dpa-AFX: Regeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular Lyphoma |
| 25.03 12:13 | dpa-AFX: *REGENERON: FDA ISSUES CRLS FOR ODRONEXTAMAB BLA IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA AND R/R DIFFUSE LARGE B-CELL LYMPHOMA |
| 11.03 12:33 | dpa-AFX: Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8 |
| 11.03 12:15 | dpa-AFX: *REGENERON PHARMA: FDA APPROVES PRALUENT INJECTION TO TREAT CHILDREN WITH GENETIC FORM OF HIGH CHOLESTEROL |
| 23.02 07:36 | dpa-AFX: Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation |
| 21.02 13:50 | dpa-AFX: Regeneron: Linvoseltamab BLA To Treat RR/MM Accepted For FDA Priority Review |
| 21.02 13:12 | dpa-AFX: *REGENERON PHARMA: FDA ACCEPTS FOR PRIORITY REVIEW BLA FOR LINVOSELTAMAB FOR TREATMENT OF R/R MULTIPLE MYELOMA |
| 16.02 07:36 | dpa-AFX: Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment |
| 06.02 12:33 | dpa-AFX: *DZ BANK RAISES FW FÜR REGENERON PHARMACEUTICALS TO 1068 (915) USD - 'BUY' |
| 06.02 12:33 | dpa-AFX: *DZ BANK HEBT FW FÜR REGENERON PHARMACEUTICALS AUF 1068 (915) USD - 'KAUFEN' |
| 02.02 13:00 | dpa-AFX: ROUNDUP: Regeneron Pharma Q4 Results Top Estimates |
| 02.02 12:44 | dpa-AFX: Regeneron Pharmaceuticals Q4 Profit Decreases, but beats estimates |
| 02.02 12:43 | dpa-AFX: *REGENERON Q4 NON-GAAP NET INCOME $1.366 BLN VS $1.449 BLN LAST YEAR |
| 02.02 12:41 | dpa-AFX: *REGENERON Q4 TOTAL REVENUES $3.434 BLN VS $3.414 BLN LAST YEAR |
| 02.02 12:39 | dpa-AFX: *REGENERON Q4 REVENUES UP 1% TO $3.43 BLN |
| 02.02 12:38 | dpa-AFX: Regeneron Pharmaceuticals: EMA To Review Marketing Authorization Application For Linvoseltamab |
|
|
